4//SEC Filing
Dunlop A. Sinclair 4
Accession 0001193125-25-240563
CIK 0001492422other
Filed
Oct 14, 8:00 PM ET
Accepted
Oct 15, 8:12 PM ET
Size
9.1 KB
Accession
0001193125-25-240563
Insider Transaction Report
Form 4
Dunlop A. Sinclair
Director
Transactions
- Other
Common Stock
2025-06-24−4,787→ 153,606 total - Other
Common Stock
2025-10-10−3,837→ 0 total(indirect: Indirect Owner (Epidarex)) - Sale
Common Stock
2025-10-10$23.72/sh−31,092$737,536→ 3,837 total(indirect: Indirect Owner (Epidarex))
Footnotes (6)
- [F1]Represents a stock transfer from the reporting person to Epidarex Capital I LP ("Epidarex"), for no consideration.
- [F2]These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Epidarex on June 20, 2025.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.47 to $23.93, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F4]Reflects a transfer of 4,787 shares of common stock for no consideration from the reporting person to Epidarex that occurred on June 24, 2025.
- [F5]The securities are held by Epidarex, and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
- [F6]Represents a stock distribution from Epidarex to a Limited Partner and General Partner of Epidarex, for no consideration.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001721108
Filing Metadata
- Form type
- 4
- Filed
- Oct 14, 8:00 PM ET
- Accepted
- Oct 15, 8:12 PM ET
- Size
- 9.1 KB